Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.

ABSTRACT:

SUBMITTER: Shipman WD 

PROVIDER: S-EPMC10947518 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature